A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group

References

• Alazzam M, Tidy J, Hancock BW, Osborne R. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2009;1:CD007102.
   Google Scholar
• Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am 2012;26:111–31.
   PubMed Web of Science ®Google Scholar
• Lurain JR. Gestational trophoblastic disease II: Classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol 2011;204:11–8.
   PubMed Web of Science ®Google Scholar
• Chapman-Davis E, Hoekstra AV, Rademaker AW, Schink JC, Lurain JR. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: Factors associated with resistance to single-agent methotrexate chemotherapy. Gynecol Oncol 2012;125:572–5.
   PubMed Web of Science ®Google Scholar
• El-Helw LM, Hancock BW. Treatment of metastatic gestational trophoblastic neoplasia. Lancet Oncol 2007;8: 715–24.
   PubMed Web of Science ®Google Scholar
• Barter JF, Soong SJ, Hatch KD, Orr JW, Jr, Partridge EC, Austin JM, Jr, et al. Treatment of nonmetastatic gestational trophoblastic disease with sequential intramuscular and oral methotrexate. Gynecol Oncol 1989;33:82–4.
   PubMed Web of Science ®Google Scholar
• Barter JF, Soong SJ, Hatch KD, Orr JW, Jr, Partridge EC, Austin JM, Jr, et al. Treatment of nonmetastatic gestational trophoblastic disease with oral methotrexate. Am J Obstet Gynecol 1987;157:1166–8.
   PubMed Web of Science ®Google Scholar
• Lybol C, Thomas CM, Blanken EA, Sweep FC, Verheijen RH, Westermann AM, et al. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Eur J Cancer 2013;49:860–7.
   PubMed Web of Science ®Google Scholar
• Deng L, Zhang J, Wu T, Lawrie TA. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev 2013; 1:CD005196.
   Google Scholar
• Rustin GJ, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996;14:2769–73.
   PubMed Web of Science ®Google Scholar
• Hoogland HJ, Arends JW, Blijham GH, Braat SH, de Haan J, van Krimpen C. Death from chemotherapy in gestational trophoblastic disease. Eur J Obstet Gynecol Reprod Biol 1988;29:167–72.
   PubMed Web of Science ®Google Scholar
• Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, et al. EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients. J Clin Oncol 1997;15:2636–43.
   PubMed Web of Science ®Google Scholar
• Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: Good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 2013;31:280–6.
   PubMed Web of Science ®Google Scholar
• Niemann I, Hansen ES, Sunde L. The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy. Gynecol Oncol 2007;104: 411–5.
   PubMed Web of Science ®Google Scholar
• FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obstet 2002;77:285–7.
   PubMed Web of Science ®Google Scholar
• Sita-Lumsden A, Short D, Lindsay I, Sebire NJ, Adjogatse D, Seckl MJ, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009. Br J Cancer 2012;107:1810–4.
   PubMed Web of Science ®Google Scholar
• Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: A gynecologic oncology group study. J Clin Oncol 2011;29:825–31.
   PubMed Web of Science ®Google Scholar
• Gilani MM, Yarandi F, Eftekhar Z, Hanjani P. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust N Z J Obstet Gynaecol 2005;45:161–4.
   PubMed Web of Science ®Google Scholar
• Khan F, Everard J, Ahmed S, Coleman RE, Aitken M, Hancock BW. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: Efficacy, acute and long-term effects. Br J Cancer 2003;89:2197–201.
   PubMed Web of Science ®Google Scholar
• McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, et al. Low-risk persistent gestational trophoblastic disease: Outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002;20:1838–44.
   PubMed Web of Science ®Google Scholar
• Lu WG, Ye F, Shen YM, Fu YF, Chen HZ, Wan XY, et al. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: A clinical analysis of 54 patients. Int J Gynecol Cancer 2008;18:357–62.
   PubMed Web of Science ®Google Scholar
• Khoo SK, Sidhu M, Baartz D, Yip WL, Tripcony L. Persistence and malignant sequelae of gestational trophoblastic disease: Clinical presentation, diagnosis, treatment and outcome. Aust N Z J Obstet Gynaecol 2010;50:81–6.
   PubMed Web of Science ®Google Scholar
• El-Helw LM, Coleman RE, Everard JE, Tidy JA, Horsman JM, Elkhenini HF, et al. Impact of the revised FIGO/WHO system on the management of patients with gestational trophoblastic neoplasia. Gynecol Oncol 2009; 113:306–11.
   PubMed Web of Science ®Google Scholar
• McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ. The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer 2010;102:810–4.
   PubMed Web of Science ®Google Scholar
• Lybol C, Sweep FC, Harvey R, Mitchell H, Short D, Thomas CM, et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2012;125:576–9.
   PubMed Web of Science ®Google Scholar
• Eiriksson L, Wells T, Steed H, Schepansky A, Capstick V, Hoskins P, et al. Combined methotrexate-dactinomycin: An effective therapy for low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2012;124:553–7.
   PubMed Web of Science ®Google Scholar
• Abrao RA, de Andrade JM, Tiezzi DG, Marana HR, Candido dos Reis FJ, Clagnan WS. Treatment for low-risk gestational trophoblastic disease: Comparison of single-agent methotrexate, dactinomycin and combination regimens. Gynecol Oncol 2008;108:149–53.
   PubMed Web of Science ®Google Scholar
• Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB. 5-Day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol 1994;54:76–9.
   PubMed Web of Science ®Google Scholar